Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
J Vasc Surg. 2018 Jan;67(1):157-164. doi: 10.1016/j.jvs.2017.06.075. Epub 2017 Aug 31.
Patients undergoing endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms can exhibit variations in sac behavior ranging from complete regression to expansion. We evaluated the impact of sac behavior at 1-year follow-up on late survival.
We used the Vascular Study Group of New England (VSGNE) registry from 2003 to 2011 to identify EVAR patients with 1-year computed tomography follow-up. Aneurysm sac enlargement ≥5 mm (sac expansion) and decrease ≥5 mm (sac regression) were defined per Society for Vascular Surgery guidelines. Predictors of change in sac diameter and impact of sac behavior on long-term mortality were assessed by multivariable methods.
Of 2437 patients who underwent EVAR, 1802 (74%) had complete 1-year follow-up data and were included in the study. At 1 year, 162 (9%) experienced sac expansion, 709 (39%) had a stable sac, and 931 (52%) experienced sac regression. Sac expansion was associated with preoperative renal insufficiency (odds ratio [OR], 3.4; 95% confidence interval [CI], 1.5-8.0; P < .01), urgent repair (OR, 2.7; 95% CI, 1.4-5.1; P < .01), hypogastric coverage (OR, 1.7; 95% CI, 1.1-2.7; P = .02), and type I/III (OR, 16.8; 95% CI, 7.3-39.0; P < .001) or type II (OR, 2.9; 95% CI, 2.0-4.3; P < .001) endoleak at follow-up, and sac expansion was inversely associated with smoking (OR, 0.6; 95% CI, 0.4-0.96; P = .03) and baseline aneurysm diameter (OR, 0.7; 95% CI, 0.6-0.9; P < .001). Sac regression (vs expansion or stable sac) was associated with female gender (OR, 1.8; 95% CI, 1.4-2.4; P < .001) and larger baseline aneurysm diameter (OR, 1.4; 95% CI, 1.2-1.5; P < .001) and inversely associated with type I/III (OR, 0.2; 95% CI, 0.1-0.5; P < .01) or type II endoleak at follow-up (OR, 0.2; 95% CI, 0.2-0.3; P < .001). After risk-adjusted Cox regression, sac expansion was independently associated with late mortality (hazard ratio, 1.5; 95% CI, 1.1-2.0; P = .01), even with adjustment for reinterventions and endoleak during follow-up. Sac regression was associated with lower late mortality (hazard ratio, 0.6; 95% CI, 0.5-0.7; P < .001). Long-term survival was lower (log-rank, P < .001) in patients with sac expansion (98% 1-year and 68% 5-year survival) compared with all others (99% 1-year and 83% 5-year survival).
These data suggest that an abdominal aortic aneurysm sac diameter increase of at least 5 mm at 1 year, although infrequent, is independently associated with late mortality regardless of the presence or absence of endoleak and warrants close observation and perhaps early intervention.
接受腹主动脉瘤腔内修复术 (EVAR) 的患者,其瘤囊表现出从完全消退到扩张的各种变化。我们评估了 1 年随访时瘤囊变化对晚期生存的影响。
我们使用 2003 年至 2011 年血管研究小组新英格兰 (VSGNE) 登记处的数据,确定了具有 1 年 CT 随访的 EVAR 患者。根据血管外科学会的指南,定义了瘤囊增大≥5 毫米 (瘤囊扩张) 和减少≥5 毫米 (瘤囊消退)。通过多变量方法评估了瘤囊直径变化的预测因素以及瘤囊行为对长期死亡率的影响。
在 2437 名接受 EVAR 的患者中,1802 名 (74%) 有完整的 1 年随访数据,纳入研究。1 年后,162 名 (9%) 出现瘤囊扩张,709 名 (39%) 瘤囊稳定,931 名 (52%) 瘤囊消退。瘤囊扩张与术前肾功能不全 (比值比 [OR],3.4; 95%置信区间 [CI],1.5-8.0; P <.01)、紧急修复 (OR,2.7; 95% CI,1.4-5.1; P <.01)、髂内覆盖 (OR,1.7; 95% CI,1.1-2.7; P =.02)、I/III 型 (OR,16.8; 95% CI,7.3-39.0; P <.001)或 II 型 (OR,2.9; 95% CI,2.0-4.3; P <.001)内漏在随访时相关,瘤囊扩张与吸烟 (OR,0.6; 95% CI,0.4-0.96; P =.03) 和基线瘤囊直径 (OR,0.7; 95% CI,0.6-0.9; P <.001) 呈负相关。瘤囊消退 (与扩张或稳定囊相比) 与女性 (OR,1.8; 95% CI,1.4-2.4; P <.001) 和更大的基线瘤囊直径 (OR,1.4; 95% CI,1.2-1.5; P <.001) 相关,与 I/III 型 (OR,0.2; 95% CI,0.1-0.5; P <.01) 或 II 型内漏 (OR,0.2; 95% CI,0.2-0.3; P <.001) 呈负相关。在风险调整后的 Cox 回归后,瘤囊扩张与晚期死亡率独立相关 (风险比,1.5; 95% CI,1.1-2.0; P =.01),即使在随访期间调整了再干预和内漏。瘤囊消退与晚期死亡率较低相关 (风险比,0.6; 95% CI,0.5-0.7; P <.001)。与所有其他患者 (1 年生存率为 99%,5 年生存率为 83%) 相比,瘤囊扩张的患者 (1 年生存率为 98%,5 年生存率为 68%) 长期生存率较低 (对数秩检验,P <.001)。
这些数据表明,尽管不常见,但腹主动脉瘤瘤囊直径在 1 年内增加至少 5 毫米,与晚期死亡率独立相关,无论是否存在内漏,都需要密切观察,可能需要早期干预。